Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth E Fransen van de Putte

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
European Urology Focus|August 13, 2019
Results of the York Mason Procedure with and without Concomitant Graciloplasty to Treat Iatrogenic Rectourethral FistulasMaarten J van der Doelen, Elisabeth E Fransen van de Putte, Simon Horenblas, et al.
Current Opinion in Urology|July 1, 2015
Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladderElisabeth E Fransen van de Putte, Mark A Behrendt, Garry L S Pigot, et al.
The Oncologist|April 8, 2016
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-AnalysisMing Yin, Monika Joshi, Richard P Meijer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2015
Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the NetherlandsTom J N Hermans, Elisabeth E Fransen van de Putte, Simon Horenblas, et al.
Urologia Internationalis|August 18, 2017
Endo-Urological Techniques for Benign Uretero-Ileal Strictures Have Poor Efficacy and Affect Renal FunctionElisabeth E Fransen van de Putte, Liesbeth L de Wall, Erik van Werkhoven, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 9, 2016
Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder CancerKim E M van Kessel, Lorraine M de Haan, Elisabeth E Fransen van de Putte, et al.
Urologic Oncology|September 3, 2015
Lymph node count at radical cystectomy does not influence long-term survival if surgeons adhere to a standardized templateElisabeth E Fransen van de Putte, Tom J N Hermans, Erik van Werkhoven, et al.
World Journal of Urology|July 18, 2015
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatinElisabeth E Fransen van de Putte, Laura S Mertens, Richard P Meijer, et al.
The Journal of Urology|November 25, 2015
Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?Daan J Reesink, Elisabeth E Fransen van de Putte, Erik Vegt, et al.
World Journal of Urology|June 19, 2017
Dose dense MVAC prior to radical cystectomy: a real-world experienceHomayoun Zargar, Jay B Shah, Elisabeth E Fransen van de Putte, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
European Urology Focus|August 13, 2019
Results of the York Mason Procedure with and without Concomitant Graciloplasty to Treat Iatrogenic Rectourethral FistulasMaarten J van der Doelen, Elisabeth E Fransen van de Putte, Simon Horenblas, et al.
Current Opinion in Urology|July 1, 2015
Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladderElisabeth E Fransen van de Putte, Mark A Behrendt, Garry L S Pigot, et al.
The Oncologist|April 8, 2016
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-AnalysisMing Yin, Monika Joshi, Richard P Meijer, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2015
Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the NetherlandsTom J N Hermans, Elisabeth E Fransen van de Putte, Simon Horenblas, et al.
Urologia Internationalis|August 18, 2017
Endo-Urological Techniques for Benign Uretero-Ileal Strictures Have Poor Efficacy and Affect Renal FunctionElisabeth E Fransen van de Putte, Liesbeth L de Wall, Erik van Werkhoven, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 9, 2016
Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder CancerKim E M van Kessel, Lorraine M de Haan, Elisabeth E Fransen van de Putte, et al.
Urologic Oncology|September 3, 2015
Lymph node count at radical cystectomy does not influence long-term survival if surgeons adhere to a standardized templateElisabeth E Fransen van de Putte, Tom J N Hermans, Erik van Werkhoven, et al.
World Journal of Urology|July 18, 2015
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatinElisabeth E Fransen van de Putte, Laura S Mertens, Richard P Meijer, et al.
The Journal of Urology|November 25, 2015
Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?Daan J Reesink, Elisabeth E Fransen van de Putte, Erik Vegt, et al.
World Journal of Urology|June 19, 2017
Dose dense MVAC prior to radical cystectomy: a real-world experienceHomayoun Zargar, Jay B Shah, Elisabeth E Fransen van de Putte, et al.
Pageof 3